P00001606T0076|0 9|Comparison
P00001606T0076|14 33|alkaline phosphatases
P00001606T0076|37 50|5-nucleotidase
P00008171T0000|30 47|hyperbilirubinemia
P00008171T0000|13 19|aspects
P00008997A0472|139 143|slope
P00008997A0472|4 6|CSF
P00008997A0472|34 40|CSF PCO2
P00008997A0472|8 11|HCO3
P00008997A0472|44 47|data
P00008997A0472|98 105|controls
P00008997A0472|24 31|function
P00008997A0472|60 63|rats
P00010943A0733|0 9|Flurazepam
P00010943A0733|96 97|mg
P00010943A0733|81 88|practice
P00010943A0733|69 71|use
P00010943A0733|44 47|drug
P00010943A0733|100 104|night
P00010943A0733|62 65|dose
P00012653T0045|0 3|Beta
P00012653T0045|12 17|agents
P00013683A0210|18 27|CO2 removal
P00013683A0210|68 78|ventilation
P00013683A0210|54 57|VCO2
P00013683A0210|40 52|CO2 production
P00015731A0090|92 107|dichlorphenamide
P00015731A0090|204 211|decrease
P00015731A0090|181 188|increase
P00015731A0090|156 156|p
P00015731A0090|197 200|p CO2
P00015731A0090|11 24|administration
P00015731A0090|64 76|acetazolamide
P00015731A0090|44 62|anhydrase inhibitors
P00015731A0090|78 90|methazolamide
P00015731A0090|214 215|pH
P00015731A0090|142 145|rise
P00015731A0090|191 191|p
P00015731A0090|226 230|blood
P00015731A0090|28 32|mg/kg
P00015731A0090|109 117|sulthiame
P00022143T0000|42 47|rabbit
P00022143T0000|20 30|etoperidone
P00022143T0000|36 38|rat
P00022143T0000|13 17|study
P00023348A0601|10 15|polyps
P00024600A0522|86 98|dosage regimen
P00024600A0522|44 53|advantages
P00024600A0522|11 26|HMG dosage regimen
P00025557A0100|28 28|%
P00025557A0100|7 16|CO2 content
P00025557A0100|32 38|animals
P00025557A0100|59 68|body weight
P00027739T0000|0 28|Serum gamma glutamyltransferase
P00027739T0000|59 64|cattle
P00027739T0000|34 42|diagnosis
P00027739T0000|45 56|liver disease
P00027967A0207|97 105|formation
P00027967A0207|2 9|contrast
P00027967A0207|170 174|onset
P00027967A0207|56 60|onset
P00027967A0207|20 31|HI antibodies
P00027967A0207|80 87|patients
P00027967A0207|177 183|illness
P00027967A0207|148 153|levels
P00027967A0207|161 164|days
P00027967A0207|124 133|antibodies
P00027967A0207|63 69|illness
P00029555A0861|31 42|quantitation
P00029555A0861|18 27|virus assay
P00029555A0861|49 55|methods
P00029555A0861|7 15|exception
P00029555A0861|102 134|shellfish microbiology laboratories
P00029953T0045|0 14|Characteristics
P00029953T0045|17 30|lipase activity
P00030183T0000|0 7|Takayasu
P00030183T0000|18 28|association
P00030183T0000|33 38|HLA-B5
P00030183T0000|10 16|disease
P00030937A0119|0 3|SGPT
P00030937A0119|13 45|alkaline phosphatase concentrations
P00030937A0119|72 79|subjects
P00030937A0119|5 8|SGOT
P00033873T0001|0 26|Gamma glutamyl transpeptidase
P00033873T0001|33 40|activity
P00033873T0001|53 57|fluid
P00033873T0001|28 31|GGTP
P00034935A0545|0 7|Patients
P00034935A0545|96 96|%
P00034935A0545|51 59|incidence
P00034935A0545|23 29|disease
P00034935A0545|77 89|drug treatment
P00034935A0545|62 70|psychoses
P00034935A0545|12 20|Parkinson
P00038408T0000|29 47|alpha-autoreceptors
P00038408T0000|89 91|FLA
P00038408T0000|70 85|alpha-methyldopa
P00038408T0000|9 19|stimulation
P00038408T0000|57 65|treatment
P00039271T0000|49 59|application
P00039271T0000|20 27|diazepam
P00039271T0000|12 17|action
P00039271T0000|65 67|rat
P00041512T0067|0 8|Abstracts
P00048373A0377|0 6|Removal
P00048373A0377|33 38|mucoas
P00048373A0377|78 87|epithelium
P00048373A0377|61 67|absence
P00050628A0202|71 81|proteinuria
P00050628A0202|40 44|serum
P00050628A0202|15 24|gammopathy
P00050628A0202|2 4|IgG
P00050628A0202|93 99|patient
P00050628A0202|48 55|patients
P00052597T0000|0 6|Studies
P00052597T0000|28 33|impact
P00052597T0000|48 61|Professor Dan H.
P00052597T0000|9 23|immunoglobulin E
P00052597T0000|37 43|sojourn
P00054900A0226|50 57|esterase
P00054900A0226|10 23|reaction stains
P00055040A0000|3 14|out-patients
P00055040A0000|243 254|cryoglobulin
P00055040A0000|116 125|fibrinogen
P00055040A0000|92 100|technique
P00055040A0000|104 113|deposition
P00055040A0000|192 195|skin
P00055040A0000|284 288|blood
P00055040A0000|70 87|immunofluorescence
P00055040A0000|19 36|pustulosis palmaris
P00055040A0000|138 156|degradation products
P00055040A0000|229 236|fraction
P00055040A0000|263 278|plasma fibrinogen
P00055040A0000|238 240|HPF
P00055040A0000|158 167|FR-antigen
P00056837A0000|97 105|carcinoma
P00056837A0000|5 21|mediastinoscopies
P00056837A0000|74 84|operability
P00056901A0308|27 46|hydroxy-ethyl-starch
P00056901A0308|57 64|solution
P00056901A0308|15 21|albumin
P00056901A0308|1 7|mixture
P00056901A0308|68 75|dilution
P00056901A0308|23 23|%
P00060529A0695|116 125|percentage
P00060529A0695|215 218|A.B.
P00060529A0695|75 85|0acteriuria
P00060529A0695|27 42|acquisition-rate
P00060529A0695|98 103|figure
P00060529A0695|172 175|year
P00060529A0695|145 162|practice population
P00060529A0695|95 95|%
P00060529A0695|128 132|women
P00060529A0695|12 23|control group
P00061478T0000|48 56|nutrition
P00061478T0000|4 16|complications
P00061478T0000|19 33|catheterisation
P00063680T0000|19 31|galactosaemia
P00063680T0000|8 16|diagnosis
P00064414A1098|0 4|Sings
P00064414A1098|36 49|erythropoiesis
P00066874T0000|89 95|results
P00066874T0000|61 73|contamination
P00066874T0000|100 109|experiment
P00066874T0000|21 47|fluid alpha fetoprotein levels
P00066874T0000|83 87|blood
P00072928T0000|0 13|Serum-ferritin
P00072928T0000|16 24|diagnosis
P00072928T0000|27 42|haemochromatosis
P00073344A0367|41 51|lymphocytes
P00073344A0367|14 35|phytomitogen reactivity
P00073344A0367|68 76|treatment
P00073344A0367|3 10|subjects
P00074758T0000|0 7|Patients
P00074758T0000|16 29|hypothyroidism
P00074758T0000|10 13|risk
P00083846T0000|0 6|Albumin
P00083846T0000|16 24|AMP levels
P00083846T0000|48 52|child
P00083846T0000|37 42|fluids
P00084275T0063|0 6|Preface
P00086313A0000|88 93|groups
P00086313A0000|99 103|basis
P00086313A0000|20 31|Legionnaires
P00086313A0000|33 47|disease bacteria
P00086313A0000|106 113|findings
P00086313A0000|143 157|antibody testing
P00086313A0000|11 17|strains
P00088391A0181|72 78|antigen
P00088391A0181|43 59|coumarin treatment
P00088391A0181|64 69|factor
P00088391A0181|22 29|activity
P00088391A0181|10 19|hand factor
P00089778A0000|298 313|cataract patients
P00089778A0000|3 15|concentration
P00089778A0000|58 68|plasminogen
P00089778A0000|174 178|serum
P00089778A0000|70 82|C3-complement
P00089778A0000|199 203|Fuchs
P00089778A0000|39 56|alpha 1-antitrypsin
P00089778A0000|165 170|humour
P00089778A0000|18 37|alpha 2-macroglobulin
P00089778A0000|228 235|patients
P00089778A0000|259 266|cataract
P00089778A0000|216 224|dystrophy
P00089778A0000|84 112|fibrinogen degradation products
P00089778A0000|114 116|FDP
P00089778A0000|187 194|patients
P00089778A0000|133 140|activity
P00092689A0352|12 19|patients
P00092689A0352|6 6|%
P00092689A0352|35 39|times
P00094639A0313|0 7|Prazosin
P00094639A0313|43 50|patients
P00094639A0313|27 32|volume
P00094639A0313|54 57|dose
P00094639A0313|67 68|mg
P00096241A0087|0 1|T4
P00096241A0087|130 134|weeks
P00096241A0087|116 122|infants
P00096241A0087|145 155|term infants
P00096241A0087|157 157|P
P00096241A0087|5 8|FT4I
P00096241A0087|77 82|values
P00096241A0087|136 138|EGA
P00096241A0087|38 43|groups
P00096241A0087|61 64|days
P00096241A0087|25 31|courses
P00097989A0106|42 49|patients
P00097989A0106|23 36|treatment plans
P00097989A0106|13 20|analysis
P00100540T0000|0 17|Aspirin intolerance
P00100540T0000|44 66|platelet cyclo-oxygenase
P00100540T0000|69 78|inhibition
P00100540T0000|81 87|aspirin
P00100540T0000|28 41|susceptibility
P00100791A0425|87 99|rhesus monkeys
P00100791A0425|135 144|norcocaine
P00100791A0425|5 11|results
P00100791A0425|126 132|effects
P00100791A0425|24 40|cynomolgus monkeys
P00101300A0257|43 44|T3
P00101300A0257|29 35|cancers
P00101300A0257|2 6|cases
P00101300A0257|46 47|N0
P00101300A0257|90 94|years
P00101300A0257|76 80|years
P00101300A0257|49 50|N1
P00101300A0257|63 70|followup
P00101300A0257|37 38|T1
P00101300A0257|99 104|months
P00101300A0257|40 41|T2
P00105401A0635|204 206|FT4
P00105401A0635|52 72|thyroid hormone binding
P00105401A0635|3 8|effect
P00105401A0635|17 19|DPH
P00105401A0635|210 212|FT3
P00105401A0635|122 134|clearance rate
P00105401A0635|137 151|thyroid hormones
P00105401A0635|183 201|premedication levels
P00105401A0635|170 180|maintenance
P00105401A0635|36 47|interference
P00105401A0635|75 77|TBG
P00105401A0635|11 13|CBZ
P00105903A0288|30 40|possibility
P00105903A0288|45 62|polyethylene glycol
P00105903A0288|67 69|PEG
P00105903A0288|10 17|research
P00111174A0351|146 152|stimuli
P00111174A0351|157 163|neurons
P00111174A0351|74 80|neurons
P00111174A0351|45 51|neurons
P00111174A0351|181 187|stimuli
P00111174A0351|107 110|eyes
P00111174A0351|93 99|stimuli
P00111174A0351|115 121|neurons
P00111174A0351|26 35|properties
P00112627A0542|147 151|mg/kg
P00112627A0542|86 98|normeperidine
P00112627A0542|28 32|mg/kg
P00112627A0542|0 12|Pentobarbital
P00112627A0542|132 143|alphaprodine
P00112627A0542|169 173|mg/kg
P00112627A0542|79 83|doses
P00112627A0542|125 129|mg/kg
P00112627A0542|111 121|anileridine
P00112627A0542|157 164|fentanyl
P00112627A0542|104 108|mg/kg
P00112627A0542|49 59|combination
P00113657A0628|0 5|Pb foil
P00113657A0628|39 49|improvement
P00113657A0628|11 15|gcm-2
P00114144A0189|220 231|enzyme defect
P00114144A0189|85 94|hypotheses
P00114144A0189|114 125|similarities
P00114144A0189|130 133|Type
P00114144A0189|28 32|study
P00114144A0189|159 166|Andersen
P00114144A0189|56 69|result emphasis
P00114144A0189|136 157|glycogen storage disease
P00114144A0189|169 175|disease
P00115974A0576|59 62|days
P00115974A0576|3 8|groups
P00115974A0576|35 38|maze
P00115974A0576|65 67|age
P00117748T0000|15 35|clindamycin resistance
P00117748T0000|0 11|Erythromycin
P00117748T0000|68 78|skin lesions
P00117748T0000|38 63|Corynebacterium diphtheriae
P00118044A0000|115 125|EMG activity
P00118044A0000|59 63|peaks
P00118044A0000|14 26|displacements
P00118044A0000|75 81|terms M1
P00118044A0000|29 34|monkey
P00118044A0000|83 84|M2
P00118044A0000|37 41|wrist
P00118044A0000|66 73|activity
P00118044A0000|140 146|muscles
P00118044A0000|89 95|M3 peaks
P00118810T0001|9 15|disease
P00119339A0400|142 153|degeneration
P00119339A0400|170 179|oesophagus
P00119339A0400|94 99|strain
P00119339A0400|158 164|lesions
P00119339A0400|118 128|myocarditis
P00119339A0400|6 11|animal
P00119339A0400|75 87|T. cruzi stocks
P00122718A0500|13 20|MRF units
P00122718A0500|86 93|activity
P00122718A0500|120 127|behavior
P00122718A0500|3 10|majority
P00122718A0500|76 79|case
P00129659T0000|0 10|Variability
P00129659T0000|63 76|sex differences
P00129659T0000|17 20|Down
P00129659T0000|32 41|trisomy-21
P00129659T0000|23 30|syndrome
P00129659T0000|79 81|IQs
P00130573T0054|0 2|VII
P00131739T0001|48 57|Uzbekistan
P00131739T0001|18 24|indices
P00131739T0001|35 45|populations
P00133214T0064|4 11|concepts
P00133214T0064|40 43|USSR
P00133214T0064|27 34|function
P00136175A1137|44 50|density
P00136175A1137|98 105|exercise
P00136175A1137|75 82|exercise
P00136175A1137|140 150|enlargement
P00136175A1137|3 13|maintenance
P00136175A1137|95 95|h
P00136175A1137|67 72|amount
P00136175A1137|111 114|week
P00136175A1137|153 155|ECA
P00137671A0896|100 110|coagulation
P00137671A0896|5 16|observations
P00137671A0896|76 84|indicator
P00137671A0896|50 59|VIII-ratio
P00139624A0318|5 9|hours
P00139624A0318|95 98|rats
P00139624A0318|18 31|administration
P00139624A0318|34 43|colchicine
P00139624A0318|48 70|serum ceruloplasmin level
P00139624A0318|112 115|rats
P00139827A0000|0 16|Radioimmunoassays
P00139827A0000|32 43|progesterone
P00139827A0000|92 98|estriol
P00139827A0000|147 152|plasma
P00139827A0000|127 131|total
P00139827A0000|172 177|course
P00139827A0000|68 70|DHA
P00139827A0000|193 200|delivery
P00139827A0000|45 66|dehydroepiandrosterone
P00139827A0000|137 138|ml
P00139827A0000|19 30|pregnenolone
P00139827A0000|74 90|alpha-hydroxy-DHA
P00139827A0000|103 110|cortisol
P00142718A0156|115 130|chest radiographs
P00142718A0156|40 46|changes
P00142718A0156|68 77|metastases
P00142718A0156|93 102|99mTc-EHDP
P00142718A0156|9 16|patients
P00146327A0147|100 106|trachea
P00146327A0147|13 18|tumors
P00146327A0147|3 10|majority
P00146327A0147|93 98|larynx
P00146327A0147|65 74|incidences
P00146327A0147|110 120|stem bronchi
P00146327A0147|37 44|cavities
P00149899T0001|0 9|Prediction
P00149899T0001|29 39|development
P00149899T0001|15 19|times
P00150066A0100|33 43|coagulation
P00150066A0100|11 20|fibrinogen
P00150066A0100|52 59|thrombin
P00150066A0554|16 27|haemorrhages
P00150066A0554|35 44|prostheses
P00154430A0906|73 85|transcription
P00154430A0906|3 19|Southern technique
P00154430A0906|107 114|fragment
P00154430A0906|92 93|kb
P00154430A0906|35 46|localization
P00154430A0906|52 57|region
P00155973A0387|157 157|%
P00155973A0387|43 48|errors
P00155973A0387|213 229|minute ventilation
P00155973A0387|172 183|gas flow rates
P00155973A0387|116 141|carbon dioxide concentration
P00155973A0387|56 56|%
P00155973A0387|206 210|range
P00155973A0387|194 198|min-1
P00155973A0387|79 84|system
P00155973A0387|26 31|limits
P00155973A0387|153 155|vol
P00155973A0387|237 241|min-1
P00159600A0871|0 1|SV
P00159600A0871|84 86|SHR
P00159600A0871|17 19|SHR
P00159600A0871|149 153|curve
P00159600A0871|56 65|compliance
P00159600A0871|125 129|shift
P00159600A0871|91 99|ventricle
P00163384A0000|28 42|Bubo virginianus
P00163384A0000|3 9|carcass
P00163384A0000|80 86|Ontario
P00163384A0000|103 110|necropsy
P00163384A0000|24 26|owl
P00167544A0067|157 180|surface specimen technique
P00167544A0067|111 128|electron microscopy
P00167544A0067|8 11|ears
P00167544A0067|25 39|microdissection
P00167544A0067|64 70|regions
P00168176A0000|0 6|Patulin
P00168176A0000|83 97|silica gel column
P00168176A0000|117 123|acetate
P00168176A0000|44 55|ethyl acetate
P00168176A0000|136 141|eluant
P00168176A0000|22 39|apple butter samples
P00168176A0000|62 68|extract
P00168431T0000|0 18|Steroid glucuronides
P00168431T0000|29 33|fluid
P00168431T0000|36 39|term
P00172199A0270|101 115|cross striations
P00172199A0270|74 83|appearance
P00172199A0270|3 8|matrix
P00172199A0270|50 59|morphology
P00172199A0270|23 30|clusters
P00173860A0475|0 9|Riboflavin
P00173860A0475|179 183|acids
P00173860A0475|80 96|excretion patterns
P00173860A0475|115 123|magnitude
P00173860A0475|143 153|elimination
P00173860A0475|54 60|animals
P00173860A0475|129 140|disturbances
P00173860A0475|25 34|percentage
P00176742T0000|0 10|Polyglactin
P00176742T0000|14 29|suture absorption
P00176742T0000|50 56|enzymes
P00176742T0000|36 39|role
P00183063A0300|112 119|patients
P00183063A0300|136 143|patients
P00183063A0300|3 11|incidence
P00183063A0300|53 59|cancers
P00183063A0300|78 81|cent
P00183063A0300|35 38|cent
P00183063A0300|63 70|patinets
P00183063A0300|130 133|cent
P00183063A0300|14 26|DNCB reactions
P00183063A0300|95 99|Stage
P00183063A0300|180 185|cancer
P00183063A0300|42 46|Stage
P00183063A0300|103 108|cancer
P00183063A0300|172 176|Stage
P00188387A0975|0 6|Studies
P00188387A0975|56 63|families
P00188387A0975|44 51|children
P00188387A0975|92 103|heart disease
P00188387A0975|9 20|lipoproteins
P00188387A0975|75 76|FH
P00193088A0196|18 25|subjects
P00193088A0196|31 31|g
P00193088A0196|34 43|Metyrapone
P00193088A0196|51 59|responses
P00193587T0000|29 37|phenomena
P00193587T0000|0 12|EEG theta waves
P00193587T0000|49 56|analysis
P00193587T0000|40 45|review
P00196255A0000|0 14|REM dream content
P00196255A0000|176 186|bizarreness
P00196255A0000|99 101|ego
P00196255A0000|61 69|influence
P00196255A0000|27 36|categories
P00196255A0000|79 88|hemisphere
P00196255A0000|154 158|music
P00196255A0000|138 147|hemisphere
P00196255A0000|114 126|verbalization
P00196255A0000|167 174|salience
